Cargando…

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer

PURPOSE: For postmenopausal patients with hormone receptor-positive early breast cancer, the optimal subgroup and duration of extended endocrine therapy is not clear yet. The aim of this study using the IDEAL patient cohort was to identify a subgroup for which longer (5 years) extended therapy is be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blok, Erik J., Kroep, Judith R., Meershoek-Klein Kranenbarg, Elma, Duijm-de Carpentier, Marjolijn, Putter, Hein, Liefers, Gerrit-Jan, Nortier, Johan W. R., Rutgers, Emiel J. Th., Seynaeve, Caroline M., van de Velde, Cornelis J. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838141/ https://www.ncbi.nlm.nih.gov/pubmed/29230665 http://dx.doi.org/10.1007/s10549-017-4601-1

Ejemplares similares

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
por: de Groot, A. F., et al.
Publicado: (2019)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial
por: Lugtenberg, Rieneke T., et al.
Publicado: (2020)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival
por: Houtsma, Danny, et al.
Publicado: (2021)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
por: Charehbili, Ayoub, et al.
Publicado: (2013)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
por: de Groot, Stefanie, et al.
Publicado: (2020)

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
por: Smit, Marloes, et al.
Publicado: (2019)

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
por: Zhang, Xi, et al.
Publicado: (2023)

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan
por: Fischer, M. J., et al.
Publicado: (2017)

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2019)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study
por: Reimers, Marlies S, et al.
Publicado: (2014)

The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study
por: Lips, Daniel J, et al.
Publicado: (2011)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery
por: Meijer, Ruben P J, et al.
Publicado: (2022)

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
por: van Hellemond, Irene E. G., et al.
Publicado: (2020)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
por: Kroep, J.R., et al.
Publicado: (2015)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial
por: Slagter, Astrid E., et al.
Publicado: (2021)

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial
por: Dijkstra, Esmée A., et al.
Publicado: (2023)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study
por: de Kruijf, Esther M, et al.
Publicado: (2012)

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
por: Chen, Tom Wei-Wu, et al.
Publicado: (2023)

Sphincter preservation in patients with low rectal cancer: striking the right oncological balance
por: Luvisetto, Federico, et al.
Publicado: (2021)

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
por: Drukker, C. A., et al.
Publicado: (2014)

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients
por: Nteliopoulos, Georgios, et al.
Publicado: (2021)

Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study
por: Vollmann, Manja, et al.
Publicado: (2020)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
por: Dave, Rajiv V., et al.
Publicado: (2023)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Mammographic screening detects low-risk tumor biology breast cancers
por: Drukker, C. A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v1rvardua88p33smhhku9i6om8